ReferenceID 1833

Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim

Front Pharmacol

Epimedii Folium (EF, Epimedium brevicornu Maxim.), a traditional botanical drug, is famous for treating bone fractures, joint diseases, and several chronic illnesses. However, some studies indicated that EF could induce

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final reference record.

Reference Id
1833
Evidence Id
18423
Core Evidence Id
18423
Source Reference Id
3653
Herb2 Reference Id
HBREF004450
Subject Paper Key
HBIN025374_36386137
Pubmed Id
36386137
Doi
10.3389/fphar.2022.1015846
Paper Title
Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim
Paper Abstract
Epimedii Folium (EF, Epimedium brevicornu Maxim.), a traditional botanical drug, is famous for treating bone fractures, joint diseases, and several chronic illnesses. However, some studies indicated that EF could induce idiosyncratic drug-induced liver injury (IDILI) in the clinic. The NLRP3 inflammasome plays a crucial role in the pathogenesis of various human diseases, including IDILI. In the present study, we showed that epimedin B could specifically facilitate nigericin- or ATP-induced NLRP3 inflammasome activation under synergistic induction of mitochondrial reactive oxygen species. Moreover, epimedin B resulted in activation of Caspase-1 and IL-1β secretion in a lipopolysaccharide (LPS)-mediated susceptibility mouse model. MCC950 pretreatment completely abrogated activation of the NLRP3 inflammasome and prevented liver injury. Importantly, several studies have confirmed that some active constituents of EF could enhance activation of the NLRP3 inflammasome and may be involved in the pathogenesis of EF-IDILI. No reports are available on whether the structure-activity relationship associated with the immunostimulatory activity in EF contributes to the pathogenesis of EF-IDILI. These findings have changed our conventional understanding about the more glycogen, the more immunostimulatory activity.
Journal
Front Pharmacol
Publish Year
2022
Experiment Subject
mouse; human
Experiment Type
Animal Experiment
Phenotype Related
Idiosyncratic Drug-induced Liver Injury; Bone Fractures; Liver Injury; Joint Diseases
Paper Title Cn
Paper Title En
Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim
Bilingual Status
semi_complete